The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma
10.3760/cma.j.cn112138-20210420-00296
- VernacularTitle:CD56与新诊断多发性骨髓瘤的预后关系分析
- Author:
Chuanying GENG
1
;
Guangzhong YANG
;
Huijuan WANG
;
Huixing ZHOU
;
Zhiyao ZHANG
;
Yuan JIAN
;
Wenming CHEN
Author Information
1. 首都医科大学附属北京朝阳医院血液科, 北京 100020
- Keywords:
Multiple myeloma;
CD56;
Survival analysis;
Prognosis
- From:
Chinese Journal of Internal Medicine
2022;61(2):164-171
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the prognostic value of CD56 expression in newly diagnosed MM (NDMM).Methods:A total of 332 NDMM patients were enrolled in Beijing Chaoyang Hospital, Capital Medical University from January 1, 2011 to January 1, 2021, with a median age of 60 years and a male to female ratio of 1.2∶1. CD56 expression on myeloma cells was detected by flow cytometry before induction therapy. Overall survival (OS) and progression-free survival (PFS) data were collected. In order to reduce the confounding factors, the propensity score matching technique was used to match CD56 positive versus negative patients at a ratio of 1∶1.Results:Among 332 patients, CD56 positivity rate was 65.1% (216/332). Patients with CD56 expression had significantly longer median OS (58.4 vs. 43.1 months, P=0.024) and PFS (28.7 vs. 24.1 months, P=0.013) than those with negative CD56. Univariate Cox proportional hazards regression analyses showed that CD56 expression was positively correlated with OS ( HR=0.644, 95 %CI 0.438-0.947, P=0.025) and a favorable prognostic factor for PFS ( HR=0.646, 95 %CI 0.457-0.913, P=0.013). The favorable effect of CD56 expression on PFS was confirmed in multivariate analysis ( HR=0.705, 95 %CI 0.497-0.998, P=0.049), but OS was not affected ( P>0.05).In the propensity score matching analysis, 194 patients with 97 in each group were identified. CD56 positivity consistently predicted longer PFS (34.2 vs.25.1 months, P=0.047), but not OS (63.4 vs.43.1 months, P=0.056). Conclusion:These results demonstrate that CD56 expression is a favorable prognostic factor for PFS of newly diagnosed MM patients.
